 It was found in the treatment of HCC using p53 gene therapy that the concurrent diabetes was controlled as well. The objectives of this study are to investigate both anti-diabetic and anti-tumor role of p53 gene therapy. This is an open-labeled, randomized, active-controlled phase 2 study. p53 will be injected via the artery, which supplies blood for the tumor nodules. The study endpoints for anti-diabetic role are fasting plasma glucose FPG, postprandial glucose PPG and glycosylated hemoglobin A1C at 30 days after the start of treatment; and for antitumor effect are progression-free survival and overall survival. 